Cell line development and upstream process services

Participation in this webinar has ended. If you wish to view it, please contact us. We will send you the URL for the recorded video at a later date. Sartorius has developed CHO cell lines for over 300 projects, with 7 projects approved and more than 80 in clinical trials. The projects include IgG1, 2, 4, multi-specific antibodies, Fc fusion proteins, enzymes, hormones, new drugs, and biosimilars. Our customers range from large companies to startups, with over 70% of them being repeat clients. In this webinar, we will introduce the details of our flexible and comprehensive services, including CHO cell line development, MCB/WCB manufacturing and testing, molecular characterization, FUT8 Knock Out, provision of optimized media, and process enhancement. *We sincerely apologize, but we kindly ask that participants refrain from joining with email addresses other than those from your company or organization. Thank you for your understanding.

This event has ended. We will be exhibiting and presenting at BioProcess International Asia 2024, which will be held in Kyoto from October 21 to 23, 2024. We will introduce Sartorius's cell line development solutions that comprehensively support the commercialization of biopharmaceuticals through products, services, experience, and expertise. 【Event Overview】 Date: October 21 (Monday) 9:00 AM - October 23 (Wednesday) 5:30 PM Location: The Westin Miyako Kyoto *Pre-registration required 【Our Seminar】 Title: Fit for Future: Advancing Bioprocess Manufacturing by Identifying Top Performing Clones and Enhancing Productivity through Process Intensification Seminar Date: October 22 (Tuesday) 9:30 AM

Registration for this webinar has ended. If you wish to view it, please contact us. We will send you the URL for the recorded video at a later date. At Sartorius, we have been providing CHO cell line development services that serve as the foundation for the manufacturing of antibody and protein therapeutics. Two products developed through this service have already been launched, and over 40 molecules are currently in clinical development. This webinar will be divided into two parts to introduce this service. In Part 1, we will present the technical upgrades of this service. In Part 2, we will introduce the media products and related services that have been optimized for this service and are now available for general sale. [Seminar Overview] April 6, 2023 (Thursday) 15:00 (approximately 50 minutes) Webinar recorded broadcast [Japanese, free] *We sincerely apologize, but participation from companies in the same industry and email addresses other than those of your organization is not permitted. Thank you for your understanding.

Participation in this webinar has ended. If you wish to view it, please contact us. We will send you the URL for the recorded video at a later date. There is a growing need to obtain CHO cell lines with high expression levels in as short a time as possible for the development and manufacturing of protein drugs such as antibody therapeutics. Sartorius' Cellca cell line development service has developed over 140 CHO cell lines to date, which are used for commercial or clinical trial manufacturing. In this webinar, we will introduce the technical background, service formats (contract and licensing), as well as the characterization tests and safety tests for antibody drugs, protein drugs, and various cells (gene and cell therapy, vaccines, etc.). *We sincerely apologize, but participation from email addresses other than those of your company or organization is not permitted. Thank you for your understanding.